• Deutsche Bank maintains a "Buy" rating for Sanofi (NASDAQ:SNY), adjusting the price target from EUR 110 to EUR 105.
• Sanofi achieves significant milestones with the approval of innovative medicines Myqorzo and Redemplo in China.
• The current stock price of $46.59 reflects a decrease of approximately 1.86%, with a year's trading range showing some volatility.

Sanofi (NASDAQ:SNY) is a global healthcare leader engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company focuses on providing innovative solutions in the fields of vaccines, rare diseases, multiple sclerosis, oncology, immunology, and cardiovascular diseases. Sanofi competes with other pharmaceutical giants like Pfizer and GlaxoSmithKline.

On January 16, 2026, Deutsche Bank maintained its "Buy" rating for Sanofi, with the stock trading at $46.63. Despite this positive rating, the action remains on hold, indicating a cautious approach. Deutsche Bank also adjusted Sanofi's price target from EUR 110 to EUR 105, reflecting a more conservative outlook.

Sanofi has recently achieved a significant milestone with the approval of two innovative medicines, Myqorzo and Redemplo, by China's National Medical Products Administration. Myqorzo treats obstructive hypertrophic cardiomyopathy, while Redemplo targets triglyceride levels in patients with familial chylomicronemia syndrome. This development highlights Sanofi's commitment to the Chinese market.

The current stock price of SNY on the NASDAQ is $46.59, showing a decrease of approximately 1.86%. The stock has fallen by $0.89 today, with a trading range from $46.49 to $47.03. Over the past year, the stock has seen a high of $60.12 and a low of $44.62, indicating some volatility.

Sanofi's market capitalization is approximately $113.5 billion, with a trading volume of 1,517,570 shares. This substantial market cap reflects the company's strong position in the pharmaceutical industry, despite recent fluctuations in stock price.